☰

Daniel C Rabe, PhD - Publications

Affiliations: 
2009-2011 Urologic Oncology Branch National Cancer Institue-NIH 
 2017- Harvard Medical School - Massachusetts General Hospital 
Tree Info Similar researchers PubMed Report error

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, et al. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. Plos One. 17: e0276211. PMID 36215283 DOI: 10.1371/journal.pone.0276211  0.5
2022 Porter RL, Sun S, Flores MN, Berzolla E, You E, Phillips IE, Kc N, Desai N, Tai EC, Szabolcs A, Lang ER, Pankaj A, Raabe MJ, Thapar V, Xu KH, ... ... Rabe DC, et al. Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor immunosuppressive phenotype. The Journal of Clinical Investigation. PMID 35708912 DOI: 10.1172/JCI155931  0.32
2021 Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, et al. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. Plos One. 16: e0261994. PMID 34941969 DOI: 10.1371/journal.pone.0261994  0.5
2021 Rabe DC, Walker ND, Rustandy FD, Wallace J, Lee J, Stott SL, Rosner MR. Tumor Extracellular Vesicles Regulate Macrophage-Driven Metastasis through CCL5. Cancers. 13. PMID 34298673 DOI: 10.3390/cancers13143459  0.606
2019 Lee J, Yesilkanal AE, Wynne JP, Frankenberger C, Liu J, Yan J, Elbaz M, Rabe DC, Rustandy FD, Tiwari P, Grossman EA, Hart PC, Kang C, Sanderson SM, Andrade J, et al. Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. Nature. PMID 30842661 DOI: 10.1038/S41586-019-1005-X  0.596
2018 Lee J, Yesilkanal A, Frankenberger C, Elbaz M, Rabe D, Yan J, Rustandy F, Hart P, Kang C, Grossman E, Locasale J, Nomura D, Bonini M, Rosner M. Abstract 5497: Effective combination therapy for breast cancer targeting BACH1 and mitochondrial metabolism Cancer Research. 78: 5497-5497. DOI: 10.1158/1538-7445.Am2018-5497  0.646
2018 Yesilkanal AE, Rabe DC, Tiwari P, Frankenberger C, Johnson GL, Rosner M. Abstract 4179: A novel approach for antimetastatic therapies against TNBC utilizing a physiologic suppressor Tumor Biology. DOI: 10.1158/1538-7445.Am2018-4179  0.513
2018 Rabe DC, Lee J, Rustandy F, Rosner MR. Abstract 1739: Tumor extracellular vesicles are required for tumor-associated macrophage programming Immunology. DOI: 10.1158/1538-7445.Am2018-1739  0.586
2018 Lee MM, Rabe DC, McKee TC, Woldemichael GM, Vasselli JR, McMahon JB, Linehan WM, Bottaro DP. Abstract A127: The identification and development of selective natural product inhibitors of hypoxia inducible factor-2α for the treatment of renal cell carcinoma Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A127  0.576
2016 Bainer R, Frankenberger C, Rabe D, An G, Gilad Y, Rosner MR. Gene expression in local stroma reflects breast tumor states and predicts patient outcome. Scientific Reports. 6: 39240. PMID 27982086 DOI: 10.1038/Srep39240  0.63
2016 Kaye DR, Pinto PA, Cecchi F, Reilly J, Semerjian A, Rabe DC, Gupta G, Choyke PL, Bottaro DP. Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. Plos One. 11: e0157130. PMID 27300295 DOI: 10.1371/Journal.Pone.0157130  0.534
2016 Lee J, Bainer R, Frankenberger C, Rabe D, Saleh s, Park M, An G, Gilad Y, Rosner MR. Abstract B15: Metastatic breast tumors regulate gene expression at distal mammary sites that predicts patient outcome Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-B15  0.652
2016 Yesilkanal AE, Frankenberger C, Rabe DC, Johnson GL, Rosner MR. Abstract 1620: Elucidating metastatic signaling networks in TNBC by investigating RKIP-regulated kinome Cancer Research. 76: 1620-1620. DOI: 10.1158/1538-7445.Tummet15-B23  0.658
2015 Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, Keer H, Miles D, Müller T, Rabe DC, Cecchi F, Bottaro DP, LoRusso P. Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Investigational New Drugs. PMID 26407571 DOI: 10.1007/S10637-015-0287-6  0.559
2015 Frankenberger C, Rabe D, Bainer R, Sankarasharma D, Chada K, Krausz T, Gilad Y, Becker L, Rosner MR. Metastasis suppressors regulate the tumor microenvironment by blocking recruitment of pro-metastatic tumor-associated macrophages. Cancer Research. PMID 26238785 DOI: 10.1158/0008-5472.Can-14-3394  0.659
2015 Cecchi F, Lih CJ, Lee YH, Walsh W, Rabe DC, Williams PM, Bottaro DP. Expression array analysis of the hepatocyte growth factor invasive program. Clinical & Experimental Metastasis. 32: 659-76. PMID 26231668 DOI: 10.1007/S10585-015-9735-0  0.63
2015 Rabe DC, Frankenberger CA, Bainer R, Sankarasharma D, Chada K, Krausz T, Gilad Y, Rosner MR. Abstract B35: The role of tumor associated macrophages (TAMs) in triple-negative breast cancer (TNBC) invasion revealed by species-specific RNA sequencing Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-B35  0.662
2015 Frankenberger CA, Bainer RO, Rabe DC, Saleh S, Park M, Gilad Y, Rosner MR. Abstract A43: Systemic tumor-stroma interactions are prognostic indicators of breast tumor invasiveness Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-A43  0.651
2015 Rabe DC, Frankenberger C, Bainer R, Sankarasharma D, Chada K, Krausz T, Gilad Y, Becker L, Rosner MR. Abstract 1557: Metastasis suppressors regulate the tumor microenvironment by blocking recruitment of prometastatic TAMs Cancer Research. 76: 1557-1557. DOI: 10.1158/1538-7445.Am2016-1557  0.676
2015 Yesilkanal AE, Frankenberger C, Rabe D, Johnson GL, Rosner MR. Abstract 3251: Regulation of TNBC kinome by the metastasis suppressor Raf kinase inhibitory protein (RKIP) Cancer Research. 75: 3251-3251. DOI: 10.1158/1538-7445.Am2015-3251  0.654
2015 Cecchi F, Lih CJ, Lee YH, Walsh W, Rabe DC, Williams PM, Bottaro DP. Expression array analysis of the hepatocyte growth factor invasive program Clinical and Experimental Metastasis. DOI: 10.1007/s10585-015-9735-0  0.48
2014 Bainer R, Frankenberger C, Rabe D, Saleh S, Park M, Chada K, Gilad Y, Rosner M. Abstract LB-320: Systemic tumor-stroma interactions are prognostic indicators of breast tumor invasiveness Molecular and Cellular Biology. DOI: 10.1158/1538-7445.Am2014-Lb-320  0.608
2014 Rabe DC, Frankenberger C, Bainer R, Gilad Y, Rosner MR. Abstract 1084: Triple-negative breast cancer displays a unique subset of macrophages dependent on CCL5 signaling Cancer Research. 74: 1084-1084. DOI: 10.1158/1538-7445.Am2014-1084  0.663
2013 Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. Plos One. 8: e54014. PMID 23516391 DOI: 10.1371/Journal.Pone.0054014  0.565
2013 Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee F, Kallender H, Cecchi F, Rabe DC, Keer H, Martin A, Liu Y, Gagnon R, Bonate P, et al. Patient enrollment and participation flow chart. Plos One. DOI: 10.1371/Journal.Pone.0054014.G001  0.473
2012 McKee TC, Rabe D, Bokesch HR, Grkovic T, Whitson EL, Diyabalanage T, Van Wyk AW, Marcum SR, Gardella RS, Gustafson KR, Linehan WM, McMahon JB, Bottaro DP. Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges. Journal of Natural Products. 75: 1632-6. PMID 22928967 DOI: 10.1021/Np300211X  0.571
2012 Cecchi F, Pajalunga D, Fowler CA, Uren A, Rabe DC, Peruzzi B, Macdonald NJ, Blackman DK, Stahl SJ, Byrd RA, Bottaro DP. Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. Cancer Cell. 22: 250-62. PMID 22897854 DOI: 10.1016/J.Ccr.2012.06.029  0.586
2012 Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opinion On Therapeutic Targets. 16: 553-72. PMID 22530990 DOI: 10.1517/14728222.2012.680957  0.637
2012 Bokesch HR, Gardella RS, Rabe DC, Bottaro DP, Linehan WM, McMahon JB, McKee TC. ChemInform Abstract: A New Hypoxia Inducible Factor-2 Inhibitory Pyrrolinone Alkaloid from Roots and Stems of Piper sarmentosum. Cheminform. 43: no-no. DOI: 10.1002/CHIN.201208208  0.455
2011 Cecchi F, Pajalunga D, Fowler A, Rabe DC, Peruzzi B, MacDonald NJ, Blackman DK, Stahl SJ, Byrd A, Bottaro DP. A hepatocyte growth factor antagonist engineered by site-directed mutagenesis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10528. PMID 28021761 DOI: 10.1200/Jco.2011.29.15_Suppl.10528  0.487
2011 Cecchi F, Rabe DC, Bottaro DP. The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer. Current Signal Transduction Therapy. 6: 146-151. PMID 25197268 DOI: 10.2174/157436211795659955  0.641
2011 Bokesch HR, Gardella RS, Rabe DC, Bottaro DP, Linehan WM, McMahon JB, McKee TC. A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum. Chemical & Pharmaceutical Bulletin. 59: 1178-9. PMID 21881266 DOI: 10.1248/Cpb.59.1178  0.51
2011 Grkovic T, Whitson EL, Rabe DC, Gardella RS, Bottaro DP, Linehan WM, McMahon JB, Gustafson KR, McKee TC. Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression. Bioorganic & Medicinal Chemistry Letters. 21: 2113-5. PMID 21353547 DOI: 10.1016/J.Bmcl.2011.01.127  0.576
2010 Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. European Journal of Cancer (Oxford, England : 1990). 46: 1260-70. PMID 20303741 DOI: 10.1016/J.Ejca.2010.02.028  0.614
2010 Cecchi F, Pajalunga D, McNeil B, Rabe D, Fowler A, Liu Y, Gagnon CR, Kallender H, Shah MA, Getzenberg R, Schoenberg M, Martin A, Srinivasan R, Linehan WM, Byrd RA, et al. Abstract SY23-03: Oncogenic signal transduction via the hepatocyte growth factor/Met receptor kinase pathway Cellular and Molecular Biology. DOI: 10.1158/1538-7445.Am10-Sy23-03  0.551
2010 Rabe DC, McKee T, Woldemichael GM, Vasselli JR, McMahon J, Linehan WM, Bottaro DP. Abstract 773: Identification and characterization of natural product-based inhibitors of hypoxia inducible factor-2 alpha Cancer Research. 70: 773-773. DOI: 10.1158/1538-7445.Am10-773  0.608
2010 Cecchi F, Pajalunga D, Rabe DC, Peruzzi B, Fowler AC, Blackman DK, MacDonald N, Stahl SJ, Byrd AR, Bottaro DP. Abstract 342: A hepatocyte growth factor antagonist engineered by disruption of heparan sulfate binding Cancer Research. 70: 342-342. DOI: 10.1158/1538-7445.Am10-342  0.589
2009 Cecchi F, Pajalunga D, Rabe D, Fowler AC, MacDonald N, Blackman DK, Stahl SJ, Byrd AR, Bottaro DP. Abstract B228: A hepatocyte growth factor antagonist engineered by targeted disruption of heparan sulfate binding Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B228  0.583
2009 Cecchi F, Liu Y, Gagnon RC, Kallender H, Rabe DC, Shah MA, Martin A, Bottaro DP. Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B210  0.547
2009 LoRusso P, Eder JP, Sherman L, McCallum S, Liu Y, Bottaro D, Cecchi F, Rabe D, Miles D, Shapiro G. Abstract A8: Final results of a phase I dose escalation study of the safety and pharmacokinetics of foretinib administered orally daily to patients with solid tumors Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A8  0.559
Show low-probability matches.